Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

A Harvard team reverses dementia in mice with a metal supplement, after showing that its deficiency drives the disease ...

Lithium could help treat cases of Alzheimer’s disease, a Harvard study suggests. People with the neurodegenerative condition ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

Years of investigation by scientists at Harvard has revealed that lithium is deeply involved in Alzheimer’s disease, a ...